PET outperforms SPECT, CCTA in diagnosing coronary artery disease

Researchers have directly compared the performance of three noninvasive imaging methods for diagnosing myocardial ischemia—and they identified positron emission tomography (PET) as the most accurate.

The study—published online Aug. 16 in JAMA Cardiology—compared coronary computed tomography angiography (CCTA), single-photon emission tomography (SPECT) and PET.

“At present, European and US guidelines do not advocate for any specific noninvasive modality over another,” wrote research team, led by Ibrahim Danad, MD, with the department of cardiology at VU University Medical Center in Amsterdam, the Netherlands. “In this controlled clinical head-to-head comparative diagnostic performance study, PET demonstrated improved accuracy compared with CCTA and SPECT for the diagnosis of coronary ischemia, as measured by fractional flow reserve (FFR), in symptomatic patients with suspected coronary artery disease.”

The study population included 208 patients who had stable, new-onset chest pain and suspected CAD (76 women, 132 men, with a mean age of 58 years).  Patients all underwent CCTA, PET, and SPECT. Within two weeks after having those imaging tests, the patients underwent invasive coronary angiography and FFR measurements of all their coronary arteries. 

In addition to finding that diagnostic accuracy was highest for PET, compared with that of CCTA and SPECT, this study found no evidence to support the use of hybrid imaging methods, the use of CCTA with either SPECT or PET, even though some other investigators have promoted such a double-barreled approach.

Not only does a combined approach not enhance diagnostic accuracy, they said but the widespread use of CCTA along with SPECT or PET would also result in increased radiation exposure to patients.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.